This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 9, 2005 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
PreScription: CompoundingToday.com and Sources of Compounding Chemicals |
Vol. 9 No. 1 |
2 |
Book Review: The Medical & Surgical Practice of NaProTECHNOLOGY |
Vol. 9 No. 1 |
5 |
Literature Reviews |
Vol. 9 No. 1 |
5 |
USP Chapter <797>: Practical Solutions for Microbiology, Sterility, and Pyrogen Testing |
Vol. 9 No. 1 |
11 |
Using ACDs in the Practice of Pharmacy |
Vol. 9 No. 1 |
15 |
USP Chapter <797> and Preparing for a JCAHO Survey |
Vol. 9 No. 1 |
23 |
Questions and Answers: USP Chapter <797> and JCAHO Compliance |
Vol. 9 No. 1 |
29 |
A Dialogue Concerning Contamination Control Systems: Where Does the Isolator Fit In? |
Vol. 9 No. 1 |
33 |
The Marketing Equation Your Ad Man Doesn't Want You to Know: How to Double Your Bottom Line without Spending an Extra Dime |
Vol. 9 No. 1 |
37 |
Defining Success |
Vol. 9 No. 1 |
42 |
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") |
Vol. 9 No. 1 |
44 |
Quality-Control Analytical Methods: Microbial Testing Aspects of USP <797> for Compounded Sterile Preparations |
Vol. 9 No. 1 |
47 |
Wish You Were Here: Pharmacy Museum, Weimar, Texas |
Vol. 9 No. 1 |
50 |
Barrier Isolators, Isolators, and Glove Boxes--What's the Difference? |
Vol. 9 No. 1 |
53 |
Calculations |
Vol. 9 No. 1 |
57 |
Basics of Compounding with Acids |
Vol. 9 No. 1 |
58 |
Standard Operating Procedure: Compounding with Concentrated Acids |
Vol. 9 No. 1 |
61 |
Amitriptyline Hydrochloride 10-mg/mL Injection |
Vol. 9 No. 1 |
62 |
Fentanyl 15-mg/mL Injection, Preservative Free |
Vol. 9 No. 1 |
63 |
Gabapentin 2-mg/mL Injection, Preservative Free |
Vol. 9 No. 1 |
64 |
Guaifenesin 50-mg/mL Injection |
Vol. 9 No. 1 |
65 |
Lidocaine Hydrochloride-2%, Ketolorac Tromethamine-3%, and Clonidine Hydrochloride-0.1% Injection |
Vol. 9 No. 1 |
66 |
Naltrexone Hydrochloride 1.4-mg/mL Injection, Preservative Free |
Vol. 9 No. 1 |
67 |
Naproxen Sodium 100-mg/mL Injection |
Vol. 9 No. 1 |
68 |
Phenol 8% Injection |
Vol. 9 No. 1 |
69 |
Tolazoline Hydrochloride 25-mg/mL Injection |
Vol. 9 No. 1 |
70 |
Tramadol Hydrochloride 50-mg/mL Injection, Preservative Free |
Vol. 9 No. 1 |
71 |
Chemical Stability of Metoclopramide Hydrochloride Injection Diluted with 0.9% Sodium Chloride Injection in Polypropylene Syringes at Room Temperature |
Vol. 9 No. 1 |
72 |
Physical characteristics of selected over-the-counter medications |
Vol. 9 No. 1 |
75 |
Stability of an Extemporaneously Compounded Propylthiouracil Suspension |
Vol. 9 No. 1 |
82 |
Scientific and Professional Reviewers for 2004 |
Vol. 9 No. 1 |
87 |
PostScription: Pharmacy, Pharmacists, and Pharmacy Practice |
Vol. 9 No. 1 |
88 |
Prescription: Too Much Information? |
Vol. 9 No. 2 |
90 |
Book Review: Bacteria for Breakfast: Probiotics for Good Health |
Vol. 9 No. 2 |
93 |
Book Review: Miracle Cure: How to Solve America's Health Care Crisis and Why Canada Isn't the Answer |
Vol. 9 No. 2 |
93 |
Literature Reviews |
Vol. 9 No. 2 |
94 |
N-acetylcysteine Used to Decrease the Incidence of Contrast-Induced Nephropathy Following Radiographic Procedures: A Literature Review |
Vol. 9 No. 2 |
99 |
Treatment of Mercury Intoxication With Dimercaptopropanesulfonate |
Vol. 9 No. 2 |
105 |
What a Pharmacist Needs to Know about Bariatric Surgery: Compounding Opportunities |
Vol. 9 No. 2 |
111 |
Combating Cardiovascular Disease With Compounded Medications. Part 1: Combination Cardiac Medicines to Control Blood Pressure |
Vol. 9 No. 2 |
117 |
Use of Domperidone as a Prokinetic and Antiemetic |
Vol. 9 No. 2 |
120 |
Proposed Revisions to USP Chapter <797> Pharmaceutical Compounding--Sterile Preparations |
Vol. 9 No. 2 |
127 |
Communication Makes It or Breaks It |
Vol. 9 No. 2 |
133 |
Quality-Control Analytical Methods: Chemical Testing Aspects of USP <797> for Compounded Sterile Preparations |
Vol. 9 No. 2 |
136 |
Basics of Compounding for Hair Care--Part I: Medicated Shampoos |
Vol. 9 No. 2 |
140 |
Standard Operating Procedure: SOP Master Book--Maintenance |
Vol. 9 No. 2 |
145 |
Calculations |
Vol. 9 No. 2 |
146 |
Aspirin 30-mg/mL Desensitization Oral Liquid, Nonaqueous |
Vol. 9 No. 2 |
147 |
Capsaicin 0.2-mg Troches |
Vol. 9 No. 2 |
148 |
Clobetasol Topical Spray |
Vol. 9 No. 2 |
149 |
Clobetasol and Dyclonine Oral Paste |
Vol. 9 No. 2 |
150 |
Homatropine 3-mg Rapid Dissolving Tablets |
Vol. 9 No. 2 |
151 |
Isosorbide Dinitrate 0.1% Topical Spray |
Vol. 9 No. 2 |
152 |
Sildenafil 1% Vaginal Cream or Gel |
Vol. 9 No. 2 |
153 |
Sildenafil Vaginal Suppository |
Vol. 9 No. 2 |
154 |
Silver Sulfadiazine 1% and Fluriprofen 2% Cream |
Vol. 9 No. 2 |
155 |
Thiabendazole 15% Cream |
Vol. 9 No. 2 |
156 |
In Vitro Evaluation of Extemporaneously Compounded Slow-Release Capsules Containing Morphine Sulfate or Oxycodone Hydrochloride |
Vol. 9 No. 2 |
157 |
Chemical Stability of Isoniazid in an Oral Liquid Dosage Form |
Vol. 9 No. 2 |
165 |
PostScription: Experts Everywhere |
Vol. 9 No. 2 |
167 |
PreScription: Working Together: Lessons from a Rope |
Vol. 9 No. 3 |
170 |
Book Reviews: Veterinary Drug Handbook: Client Information Edition |
Vol. 9 No. 3 |
173 |
Book Reviews: When Change Is Your Company's Middle Name: The Professional's Guide to Understanding the Human Side of Business Transformation |
Vol. 9 No. 3 |
173 |
Literature Reviews |
Vol. 9 No. 3 |
174 |
Update on Transdermals for Animal Patients |
Vol. 9 No. 3 |
178 |
Compounding for Behavior Problems in Animals |
Vol. 9 No. 3 |
185 |
Compounding Antiangiogenic Cancer Therapy for Animals |
Vol. 9 No. 3 |
195 |
Combating Cardiovascular Disease with Compounded Medications -- Part 2: Clinical and Compounding Issues for Antihypertensive Drugs |
Vol. 9 No. 3 |
201 |
Quality-Control Analytical Methods: Determination of Tapped Bulk Volume for Compounded Prescriptions |
Vol. 9 No. 3 |
207 |
Survey of State Veterinary Compounding Laws and Regulations |
Vol. 9 No. 3 |
209 |
What Customers Want |
Vol. 9 No. 3 |
213 |
Basics of Compounding for Hair Care -- Part 2: Medicated Conditions |
Vol. 9 No. 3 |
215 |
Pharmacy History: Pharmacy Knots |
Vol. 9 No. 3 |
220 |
Standard Operating Procedure: Exhaust System Airflow Monitoring (Individual Capsule Stations) |
Vol. 9 No. 3 |
222 |
Calculations |
Vol. 9 No. 3 |
224 |
Calcitriol 100 ng/mL Oral Liquid, Veterinary |
Vol. 9 No. 3 |
225 |
Dexamethasone Oral Powder 10-mg Units, Veterinary |
Vol. 9 No. 3 |
226 |
Dipyrone 500-mg/mL Injection, Veterinary |
Vol. 9 No. 3 |
227 |
Meloxicam 0.2 mg/mL Oral Liquid, Veterinary |
Vol. 9 No. 3 |
228 |
Methimazole 10-mg/mL Oral Liquid, Veterinary |
Vol. 9 No. 3 |
229 |
Metronidazole 1% and Silver Sulfadiazine 1% Cream, Veterinary |
Vol. 9 No. 3 |
230 |
Pergolide 500-mcg Capsules, Veterinary |
Vol. 9 No. 3 |
231 |
Pergolide 0.2-mg/mL Oral Liquid, Veterinary |
Vol. 9 No. 3 |
232 |
Phenoxybenzamine Hydrochloride 5-mg Capsules, Veterinary |
Vol. 9 No. 3 |
233 |
Piroxicam 2-mg/mL Oral Liquid, Veterinary |
Vol. 9 No. 3 |
234 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration |
Vol. 9 No. 3 |
235 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration |
Vol. 9 No. 3 |
238 |
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study |
Vol. 9 No. 3 |
242 |
PostScription: AVMA's Position on Compounding for Animals |
Vol. 9 No. 3 |
247 |
Prescription: Support Your Local College of Pharmacy |
Vol. 9 No. 4 |
250 |
Book Reviews: Awakening Athena: Resilience, Restoration, and Rejuvenation for Women |
Vol. 9 No. 4 |
252 |
Book Reviews: Perfect Balance |
Vol. 9 No. 4 |
253 |
Literature Reviews |
Vol. 9 No. 4 |
254 |
Testosterone Replacement Therapy for Female Androgen Insufficiency Syndrome |
Vol. 9 No. 4 |
259 |
Guidelines for Consulting with Patients about Bioidentical Hormone Replacement Therapy |
Vol. 9 No. 4 |
266 |
Hypothyroidism: Optimizing Therapy with Slow-Release Compounded Thyroid Replacement |
Vol. 9 No. 4 |
268 |
Compounding for Endocrine Disorders in Adult Patients |
Vol. 9 No. 4 |
275 |
Natural Progesterone Handout |
Vol. 9 No. 4 |
281 |
Considerations for Choosing a Primary Engineering Control for Compounding Sterile Products |
Vol. 9 No. 4 |
284 |
Local Ventilation for Safe Containment in the Pharmaceutical Industry |
Vol. 9 No. 4 |
293 |
Quality-Control Analytical Methods: Glossary of Quality Control/Quality Assurance Terms in Pharmaceutical Compounding |
Vol. 9 No. 4 |
300 |
Basics of Pharmacogenomics for the Compounding Pharmacist |
Vol. 9 No. 4 |
303 |
Calculations |
Vol. 9 No. 4 |
307 |
Standard Operating Procedure: Employee Personnel Records |
Vol. 9 No. 4 |
309 |
BMS Mouthwash |
Vol. 9 No. 4 |
310 |
Bonain's Solution |
Vol. 9 No. 4 |
311 |
Brompton's Mixture |
Vol. 9 No. 4 |
312 |
Bunnel's Solutions |
Vol. 9 No. 4 |
313 |
Burow's Solution |
Vol. 9 No. 4 |
314 |
Joulie's Solution |
Vol. 9 No. 4 |
315 |
Shohl's Solution, Modified (Albright's Solution) |
Vol. 9 No. 4 |
316 |
Suby-Albright Solution "G" Irrigation |
Vol. 9 No. 4 |
317 |
Suby-Albright Solution "M" Irrigation |
Vol. 9 No. 4 |
318 |
Whitehead's Varnish |
Vol. 9 No. 4 |
319 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Fluorouracil and with Gemcitabine Hydrochloride during Simulated Y-site Administration |
Vol. 9 No. 4 |
320 |
Stability of Nebulizer Admixtures |
Vol. 9 No. 4 |
323 |
PostScription: Women in Balance: A Cause Worth Advancing |
Vol. 9 No. 4 |
327 |
Prescription: Pharmacy Compounding Worldwide |
Vol. 9 No. 5 |
330 |
Book Reviews: Lawsuit Lottery: The Hijacking of Justice in America |
Vol. 9 No. 5 |
332 |
Literature Reviews |
Vol. 9 No. 5 |
333 |
Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain |
Vol. 9 No. 5 |
339 |
Prescription for Relief: One Woman's Experience with Intractable Nonmalignant Pain |
Vol. 9 No. 5 |
349 |
A Patient's Guide to Transdermal Treatment of Pain |
Vol. 9 No. 5 |
354 |
Formulating for the Gluten-sensitive Individual |
Vol. 9 No. 5 |
357 |
Basics of Compounding: Using Chemical Conversion Factors |
Vol. 9 No. 5 |
361 |
Compounding: A Well-established Practice in 1938 |
Vol. 9 No. 5 |
364 |
Technology Update: An Overview of PDA-based Software Applications for Practicing Pharmacists |
Vol. 9 No. 5 |
369 |
Back to the Basics of Business |
Vol. 9 No. 5 |
380 |
Standard Operating Procedure: Denver Instrument Company M-120 Analytical Balance--Calibration, Cleaning, and Use |
Vol. 9 No. 5 |
382 |
Calculations |
Vol. 9 No. 5 |
384 |
Acetaminophen 400-mg, Aspirin 250-mg, Codeine Phosphate 30-mg with Antacids Capsules |
Vol. 9 No. 5 |
386 |
Acetaminophen 325-mg, Codeine Phosphate 32.5-mg, and Phenyltoloxamine Citrate 30-mg Capsules |
Vol. 9 No. 5 |
387 |
Aspirin 380-mg, Caffeine 30-mg, and Codeine Phosphate 30-mg Capsules |
Vol. 9 No. 5 |
388 |
Aspirin 325-mg, Codeine Phosphate 30-mg, Aluminum Glycinate 48.6-mg, and Magnesium Carbonate 97.2-mg Capsules |
Vol. 9 No. 5 |
389 |
Meperidine Hydrochloride 50-mg and Atropine Sulfate 0.4-mg/mL Injection |
Vol. 9 No. 5 |
390 |
Meperidine Hydrochloride 50-mg and Promethazine Hydrochloride 12.5-mg Capsules |
Vol. 9 No. 5 |
391 |
Meperidine Hydrochloride 50-mg and Promethazine Hydrochloride 25-mg Capsules |
Vol. 9 No. 5 |
392 |
Methadone Hydrochloride 0.33-mg/mL Oral Solution |
Vol. 9 No. 5 |
393 |
Morphine Sulfate 16-mg and Atropine Sulfate 0.4-mg/mL Injection |
Vol. 9 No. 5 |
394 |
Morphine Sulfate 5-mg/mL PCA Injection (Concentration May Vary) |
Vol. 9 No. 5 |
395 |
Stability and Subjective Taste Acceptability of Four Glycopyrrolate Solutions for Oral Administration |
Vol. 9 No. 5 |
396 |
Chemical Stability of Hydralazine Hydrochloride after Reconstruction in 0.9% Sodium Chloride Injection or 5% Dextrose Injection for Infusion |
Vol. 9 No. 5 |
399 |
Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations |
Vol. 9 No. 5 |
402 |
PostScription: Searching for Barrier Isolator Information? |
Vol. 9 No. 5 |
407 |
Prescription: Pediatric Formulation Initiatives |
Vol. 9 No. 6 |
410 |
Unlocking Autism: Is Compounding the Key? |
Vol. 9 No. 6 |
413 |
Compounding for a Pediatric Hospital |
Vol. 9 No. 6 |
423 |
Wiping Out Diaper Rash |
Vol. 9 No. 6 |
433 |
Pediatric Oral Liquid Preparations |
Vol. 9 No. 6 |
437 |
Marketing Your Business for Success |
Vol. 9 No. 6 |
445 |
Compounding Around the World: Portugal |
Vol. 9 No. 6 |
449 |
Profile: The McGuff Companies. Part 1: Compounding and Manufacturing Share Facilities and Build Corporate Success |
Vol. 9 No. 6 |
452 |
Basics of Compounding for Pediatric Patients: Commonly Prescribed Oral Liquid Formulations, Vehicles, and Stock Solutions |
Vol. 9 No. 6 |
456 |
Quality Control Analytical Methods: Quality Issues Related to Compounding with Commercial Products |
Vol. 9 No. 6 |
462 |
Standard Operating Procedure: Washing Glassware and Equipment Used in Compounding Nonsterile Preparations |
Vol. 9 No. 6 |
470 |
Calculations |
Vol. 9 No. 6 |
471 |
Alprazolam 1-mg/mL Oral Liquid |
Vol. 9 No. 6 |
472 |
Bethanechol 5-mg/mL Oral Liquid |
Vol. 9 No. 6 |
473 |
Clonazepam 0.1-mg/mL Oral Liquid |
Vol. 9 No. 6 |
474 |
Dolasetron 10-mg/mL Oral Liquid |
Vol. 9 No. 6 |
475 |
Ganciclovir 100-mg/mL Oral Liquid |
Vol. 9 No. 6 |
476 |
Isradipine 1-mg/mL Oral Liquid |
Vol. 9 No. 6 |
477 |
Pyrazinamide 10-mg/mL Oral Liquid |
Vol. 9 No. 6 |
478 |
Quinidine Sulfate 10-mg/mL Oral Liquid |
Vol. 9 No. 6 |
479 |
Ursodiol 25-mg/mL Oral Liquid |
Vol. 9 No. 6 |
480 |
Valganciclovir Hydrochloride 60-mg/mL Oral Liquid |
Vol. 9 No. 6 |
481 |
Chemical Stability of Fentanyl in Polypropylene Syringes and Polyvinylchloride Bags |
Vol. 9 No. 6 |
482 |
Chemical Stability of Perphenazine in Oral Liquid Dosage Forms |
Vol. 9 No. 6 |
484 |
PostScription: Compounding Pharmacies and the Successful Treatment of Autism |
Vol. 9 No. 6 |
487 |